Global Ovarian Cancer Market Holds High Demand for Maintenance Therapies as Relapse Cases Remain Above Acceptable Levels

Though ovarian cancer ranks seventh in the list of the most common types of cancers worldwide, its affliction rate continues to rise. These are the estimates of the World Cancer Research Fund International, which also states that the prevalence of this disease remarkably higher in less developed countries.

The Asia Pacific market has not only seen a rise in the number of ovarian cancer cases reported annually, but has also been a fertile playground for several new therapies to be developed.

Browse the full Asia Pacific Ovarian Cancer Market Report

Within Asia Pacific, countries where ovarian cancer pipelines are most active are: China, India, Japan and Australia. Even as this market continues to thrive and grow at a steady pace, a recent market report by GBI research carries some interesting trends. These are:

· The Asia Pacific ovarian cancer therapies market features a white space for maintenance therapies. At present, the most widely used type of chemotherapy is the platinum-based one.

The use of paclitaxel and carboplatin chemotherapy regimen is seen to be the most commonly-used one. Data shows that this is the most widely used standard of care for treating platinum-sensitive ovarian cancer in both first-line as well as recurrent cases. As the efficacy of the initial treatment is seen to be satisfactory, the remission rates continue to remain above acceptable levels. However, studies also show that nearly all patients with relapse (after they have been through remission and relapse) either succumb to ovarian cancer or develop platinum-resistant ovarian cancer.

· The prognosis for platinum-resistant ovarian cancer is currently poor, and leaves a wide gap where companies can fill with innovative solutions.

Thus, the demand for maintenance therapies is high in the Asia Pacific ovarian cancer market. Moreover, the time is right for market players to invest in developing more effective treatment solutions for patients that are afflicted with platinum-sensitive ovarian cancer.

Send An Enquiry: http://www.mrrse.com/enquiry/112

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Pathophysiology
2.1.1 Ovarian Cancer – A Group of Distinct Diseases
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways
2.2 Symptoms and Diagnosis
2.3 Risk Factors
2.3.1 Age
2.3.2 Inherited Genetic Mutations
2.3.3 Greater Number of Lifetime Ovulations
2.3.4 Weight
2.3.5 Previous Medical Conditions
2.4 Treatment Algorithm
2.4.1 Surgery
2.4.2 First-Line Chemotherapy
2.4.3 Maintenance Therapy
2.5 Recurrent Disease

3 Marketed Products
3.1 Carboplatin
3.2 Paclitaxel
3.3 Gemcitabine
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin
3.6 Yondelis
3.7 Avastin

4 Product Pipeline

4.1 Overview of Pipeline by Phase and Route of Administration
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target
4.2.1 Molecular Targets in the Developmental Pipeline
4.3 Clinical Trials
4.3.1 Clinical Trial Duration
4.3.2 Clinical Trial Size
4.3.3 Failure Rate
4.3.4 Discussion
4.4 Late-Stage Drugs in Developmental Pipeline
4.4.1 Niraparib
4.4.2 Olaparib
4.4.3 Vargatef
4.4.4 Trebananib
4.4.5 Farletuzumab
4.4.6 Karenitecin
4.5 Discussion

5 Market Forecasts

5.1 Asia-Pacific
5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets
5.2 India
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Forecast
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Forecast
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Forecast
5.5 Australia
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Forecast
5.6 Drivers and Barriers
5.6.1 Drivers
5.6.2 Barriers

6 Deals

6.1 Licensing Deals
6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
6.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis
6.1.3 Hana Enters into Licensing Agreement with Tekmira
6.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775
6.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug
6.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical
6.1.7 Orion Enters into Agreement with Oasmia
6.1.8 Ohio University Enters into Licensing Agreement with Phosplatin
6.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo
6.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research
6.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300
6.2 Co-development Deals
6.2.1 Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma
6.2.2 Merck Enters into Co-development Agreement with Endocyte for Cancer Drug
6.2.3 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre
6.2.4 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug Discovery

About Us:

Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports.
Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice.
Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords. 

Contacts: 
State Tower
90, State Street
Suite 700
Albany, NY - 12207
United States
Telephone: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/